Verrica Pharmaceuticals Inc.

Symbol: VRCA

NASDAQ

7.07

USD

Market price today

  • -4.9240

    P/E Ratio

  • 0.0381

    PEG Ratio

  • 299.90M

    MRK Cap

  • 0.00%

    DIV Yield

Verrica Pharmaceuticals Inc. (VRCA) Financial Statements

On the chart you can see the default numbers in dynamics for Verrica Pharmaceuticals Inc. (VRCA). Companys revenue shows the average of 3.269 M which is -0.085 % gowth. The average gross profit for the whole period is 2.914 M which is 6.331 %. The average gross profit ratio is 0.332 %. The net income growth for the company last year performance is 1.421 % which equals -0.866 % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Verrica Pharmaceuticals Inc., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of 0.825. In the realm of current assets, VRCA clocks in at 77.53 in the reporting currency. A significant portion of these assets, precisely 69.547, is held in cash and short-term investments. This segment shows a change of 1.029% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 0, if any, in the reporting currency. This indicates a difference of 0.000% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 42.874 in the reporting currency. This figure signifies a year_over_year change of 28.823%. Shareholder value, as depicted by the total shareholder equity, is valued at 19.763 in the reporting currency. The year over year change in this aspect is -0.506%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 4.416, with an inventory valuation of 1.02, and goodwill valued at 0, if any. The total intangible assets, if present, are valued at 0.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016

balance-sheet.row.cash-and-short-term-investments

268.9569.534.370.4
65.5
62
89.8
8.7
0.5

balance-sheet.row.short-term-investments

00054.6
54.8
52.8
79.5
0
0

balance-sheet.row.net-receivables

8.724.40.50
0
0
0
0
0

balance-sheet.row.inventory

1.31-0.50
0
0
0
0
0

balance-sheet.row.other-current-assets

10.162.54.84
2.2
3
1.3
0.4
0

balance-sheet.row.total-current-assets

289.1377.539.174.3
65.5
65
89.8
9.1
0.5

balance-sheet.row.property-plant-equipment-net

19.23.65.65.8
4.9
2.2
0.3
0
0

balance-sheet.row.goodwill

0000
0
0
0
0
0

balance-sheet.row.intangible-assets

0000
0
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

0000
0
0
0
0
0

balance-sheet.row.long-term-investments

0000
0
0.4
0
0
0

balance-sheet.row.tax-assets

0000
0
0
0
0
0

balance-sheet.row.other-non-current-assets

1.260.500
3.7
0.8
1.8
0
0

balance-sheet.row.total-non-current-assets

20.464.15.65.8
8.7
3.4
2.1
0
0

balance-sheet.row.other-assets

0000
0
0
0
0
0

balance-sheet.row.total-assets

309.5881.644.780.1
74.2
68.4
91.9
9.1
0.5

balance-sheet.row.account-payables

7.022.50.50.8
0.3
1.2
1
0.2
0.1

balance-sheet.row.short-term-debt

1.660.70.341.9
35.5
0.1
0
0
0

balance-sheet.row.tax-payables

0000
0
0
0
0
0

balance-sheet.row.long-term-debt-total

88.5642.91.21.5
35.3
0.1
0
0
0

Deferred Revenue Non Current

0000
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-

balance-sheet.row.other-current-liab

19.2713.92.73.3
3.1
2
1.5
0.4
0.3

balance-sheet.row.total-non-current-liabilities

90.544.81.21.5
35.3
0.1
0
0
2.8

balance-sheet.row.other-liabilities

0000
-33.6
0
0
0
0

balance-sheet.row.capital-lease-obligations

6.181.91.51.7
1.9
0.2
0
0
0

balance-sheet.row.total-liab

127.2761.84.747.5
41.2
3.4
2.5
0.6
3.2

balance-sheet.row.preferred-stock

0000
0
0
91.9
0
2.8

balance-sheet.row.common-stock

0.02000
0
0
0
0
0

balance-sheet.row.retained-earnings

-787.36-230.4-163.5-139
-103.9
-61.2
-33.1
-12.4
-2.7

balance-sheet.row.accumulated-other-comprehensive-income-loss

0000
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

969.65250.2203.5171.6
136.9
126.2
30.6
20.9
-2.8

balance-sheet.row.total-stockholders-equity

182.3119.84032.6
33
65
89.4
8.5
-2.7

balance-sheet.row.total-liabilities-and-stockholders-equity

309.5881.644.780.1
74.2
68.4
91.9
9.1
0.5

balance-sheet.row.minority-interest

0000
0
0
0
0
0

balance-sheet.row.total-equity

182.3119.84032.6
33
65
89.4
-
-

balance-sheet.row.total-liabilities-and-total-equity

309.58---
-
-
-
-
-

Total Investments

00054.6
54.8
52.8
79.5
0
0

balance-sheet.row.total-debt

92.1645.51.543.4
35.3
0.2
0
0
0

balance-sheet.row.net-debt

-176.79-24-32.727.7
24.6
-9.1
-89.8
-8.7
-0.5

Cash Flow Statement

The financial landscape of Verrica Pharmaceuticals Inc. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of -1.055. The company recently extended its share capital by issuing 30.13, marking a difference of 0.000 compared to the previous year. Interestingly, a portion of the company's stock, specifically 0, was bought back by the company itself. This action resulted in a change of 0.000 from the previous year. Meanwhile, the company's account payables are currently standing at 2.2 in the reporting currency. The company's investing activities resulted in net cash usage, amounting to -362000.000 in the reporting currency. This is a shift of -1.007 from the previous year. In the same period, the company recorded 0.84, 0, and -44.1, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated 0 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 88.19, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016

cash-flows.row.net-income

-67-67-24.5-35.1
-42.7
-28.2
-20.6
-4.5
-1.9

cash-flows.row.depreciation-and-amortization

0.840.80.70.5
0.2
0.3
0
0
0

cash-flows.row.deferred-income-tax

01.700.1
-0.1
0
0
0
0

cash-flows.row.stock-based-compensation

14.3814.456.1
9.8
3.3
2.3
0.1
0

cash-flows.row.change-in-working-capital

9.639.9-1.8-0.5
1.6
-1.7
0.9
-0.2
0.3

cash-flows.row.account-receivables

-3.93-3.9-0.50
0
0
0
0
0

cash-flows.row.inventory

000.50
0
0
0
0
0

cash-flows.row.account-payables

2.22.2-0.30.5
-0.8
0.2
0.8
0.1
0.1

cash-flows.row.other-working-capital

11.3611.6-1.5-1
2.5
-2
0.1
-0.3
0.2

cash-flows.row.other-non-cash-items

3.351.71.91.4
0.9
-1.1
-0.4
0
0

cash-flows.row.net-cash-provided-by-operating-activities

-38.8000
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-0.36-0.4-0.3-0.9
-1.5
-0.7
-0.8
0
0

cash-flows.row.acquisitions-net

0000
0
0
0
0
0

cash-flows.row.purchases-of-investments

00-4.5-68.9
-71.7
-89.9
-79.1
0
0

cash-flows.row.sales-maturities-of-investments

005969
69.8
117.7
0
0
0

cash-flows.row.other-investing-activites

00-0.2-0.2
-0.2
-1.2
0
0
0

cash-flows.row.net-cash-used-for-investing-activites

-0.36-0.454-1
-3.6
26
-79.9
0
0

cash-flows.row.debt-repayment

-44.4-44.1-43.80
-34.2
-0.1
0
0
0

cash-flows.row.common-stock-issued

30.1530.126.928.1
0.5
0.4
86.3
0
0

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0

cash-flows.row.dividends-paid

0000
0
0
0
0
0

cash-flows.row.other-financing-activites

88.6988.205.5
68.9
0.1
13.1
12.7
0.5

cash-flows.row.net-cash-used-provided-by-financing-activities

74.4474.2-16.933.6
35.2
0.4
99.4
12.7
0.5

cash-flows.row.effect-of-forex-changes-on-cash

0000
0
0
0
0
0

cash-flows.row.net-change-in-cash

35.2735.318.55.1
1.4
-1
1.6
8.1
-1.1

cash-flows.row.cash-at-end-of-period

268.9569.534.315.8
10.7
9.2
10.3
8.7
0.5

cash-flows.row.cash-at-beginning-of-period

233.6734.315.810.7
9.2
10.3
8.7
0.5
1.7

cash-flows.row.operating-cash-flow

-38.8-38.6-18.6-27.6
-30.2
-27.4
-17.9
-4.6
-1.6

cash-flows.row.capital-expenditure

-0.36-0.4-0.3-0.9
-1.5
-0.7
-0.8
0
0

cash-flows.row.free-cash-flow

-39.16-38.9-19-28.5
-31.7
-28.1
-18.6
-4.6
-1.6

Income Statement Row

Verrica Pharmaceuticals Inc.'s revenue saw a change of -0.433% compared with the previous period. The gross profit of VRCA is reported to be 3.96. The company's operating expenses are 67.18, showing a change of 126.943% from the last year. The expenses for depreciation and amortization are 0.84, which is a 1.000% change from the last accounting period. Operating expenses are reported to be 67.18, which shows a 126.943% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a -1.969% year-over-year growth. The operating income is -63.22, which shows a 1.969% change when compared to the previous year. The change in the net income is 1.421%. The net income for the last year was -67.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016

income-statement-row.row.total-revenue

5.125.1912
0
0
0
0
0

income-statement-row.row.cost-of-revenue

0.731.20.70.5
0.2
0.3
0
0
0

income-statement-row.row.gross-profit

4.3948.311.5
-0.2
-0.3
0
0
0

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0

income-statement-row.row.research-development

20.29---
-
-
-
-
-

income-statement-row.row.selling-general-administrative

60.62---
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

-13.31---
-
-
-
-
-

income-statement-row.row.other-expenses

0.160-0.10
0
1.9
0
0
0

income-statement-row.row.operating-expenses

67.6267.229.642.9
40.2
30.1
21.9
4.5
1.9

income-statement-row.row.cost-and-expenses

68.3468.330.342.9
40.2
30.1
21.9
4.5
1.9

income-statement-row.row.interest-income

2.742.70.50.1
0.5
1.9
1.2
0
0

income-statement-row.row.interest-expense

0.1542.24.3
3
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

-13.31---
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-3.77-3.8-3.2-4.2
-2.5
1.9
0
0
0

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-

income-statement-row.row.other-operating-expenses

0.160-0.10
0
1.9
0
0
0

income-statement-row.row.total-operating-expenses

-3.77-3.8-3.2-4.2
-2.5
1.9
0
0
0

income-statement-row.row.interest-expense

0.1542.24.3
3
0
0
0
0

income-statement-row.row.depreciation-and-amortization

1.340.80.40.1
0.5
0.3
0
0
0

income-statement-row.row.ebitda-caps

-61.61---
-
-
-
-
-

income-statement-row.row.operating-income

-63.22-63.2-21.3-30.9
-40.2
-30.1
-21.9
-4.5
-1.9

income-statement-row.row.income-before-tax

-67-67-24.5-35.1
-42.7
-28.2
-20.6
-4.5
-1.9

income-statement-row.row.income-tax-expense

003.23.8
2.8
-0.3
1.2
0
0

income-statement-row.row.net-income

-66.5-67-27.7-38.9
-45.5
-27.9
-20.6
-4.5
-1.9

Frequently Asked Question

What is Verrica Pharmaceuticals Inc. (VRCA) total assets?

Verrica Pharmaceuticals Inc. (VRCA) total assets is 81597000.000.

What is enterprise annual revenue?

The annual revenue is 4905000.000.

What is firm profit margin?

Firm profit margin is 0.858.

What is company free cash flow?

The free cash flow is -0.846.

What is enterprise net profit margin?

The net profit margin is -12.977.

What is firm total revenue?

The total revenue is -12.338.

What is Verrica Pharmaceuticals Inc. (VRCA) net profit (net income)?

The net profit (net income) is -66995000.000.

What is firm total debt?

The total debt is 45510000.000.

What is operating expences number?

The operating expences are 67182000.000.

What is company cash figure?

Enretprise cash is 69547000.000.